Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03338764Phase 3Withdrawn

An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia

Role: lead

NCT04396327Phase 2Not Yet Recruiting

SM-1 vs. an Active Comparator in A Model of Transient Insomnia

Role: lead

NCT03331042Phase 3Completed

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

Role: lead

NCT02671760Phase 2Completed

Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia

Role: lead

All 4 trials loaded